Antibacterial Agents TRIZ Cases

Reversible linker conjugates sustain antibiotic release above eradication thresholds for three days, reducing resistance risk in biofilm infections.

Formula I compounds inhibit MmpL3 protein activity to treat mycobacterial infections despite resistant cell walls.

Lithium-containing calcium bone cement prevents bacterial attachment via controlled ion release, addressing biofilm resistance on implants.

3'-deoxyadenosine terminates poly A tail synthesis, restoring cyclic AMP levels depleted by excessive ATP consumption during viral replication.

Incorporating glycerol stabilizes the alpha-helical structure of silk fibroin, preventing brittleness while maintaining tensile strength.

Annealed antibiotic salt beads on biodegradable filaments provide controlled drug release without matrix formers.

Coated calcium sulfate particles bind micelles while gum arabic stabilizes emulsions, resolving insufficient lipid metabolism enhancement.

Trp8 GLP-1 analogues resist DPP-IV degradation while maintaining receptor binding affinity.

Liposome encapsulation shields peptide P33 from protease degradation while maintaining antimicrobial efficacy against Enterococcus faecalis.

Gossypol acetic acid co-crystals inhibit anti-apoptotic Bcl-2 proteins, restoring apoptosis sensitivity and overcoming chemoresistance.

A subunit vaccine composition comprising Tuf, NOX, and MS53-0285 antigens induces immunity against Mycoplasma synoviae infection in poultry.

Heat-killed Enterococcus faecalis suppresses Arg-gingipain and Lys-gingipain activities to address insufficient treatment effectiveness against P. gingivalis.

Pyrazole ACC inhibitors address unsustainable weight loss by blocking fatty acid synthesis while providing broad-spectrum fungicidal activity.

Conjugating antigens to antibody-recognition epitopes utilizes pre-existing immunity to enhance protection against infectious agents without booster shots.

Diluting an aged sodium hypochlorite stock stabilizes available chlorine concentration, preventing degradation over a six to twelve month shelf life.

Refluxing indandione with fluoro-benzaldehyde yields a novel oxonine compound that overcomes antibiotic resistance.

Recombinant endolysins target Gardnerella vaginalis cell walls to selectively kill pathogens while preserving beneficial Lactobacilli.

A bacteriophage-derived antimicrobial protein targets Staphylococcus aureus cell walls through enzymatic peptidoglycan hydrolysis.

Incorporating azadirachtin into fish feed eliminates labor-intensive bath treatments and reduces environmental pollution from chemical residues.

Bifidobacterium animalis subsp. lactis ATM-209 inhibits Helicobacter pylori growth through gastric acid tolerance and antimicrobial production.

Segmenting active ingredients by molecular weight resolves formulation complexity while targeting systemic inflammation and coagulation disorders.

Modified saponins resolve resistance and toxicity trade-offs by selectively targeting Candida biofilms while minimizing hemolysis.

Peptidomimetic compounds of formula I combat multi-drug-resistant bacteria like MRSA at low concentrations.

X-ray irradiation inactivates Staphylococcus aureus while preserving structural integrity, addressing insufficient immunogenicity against resistant strains.

A serine protease antigen vaccine induces protective antibodies against conserved Haemophilus parasuis proteins.

Crystalline solvate forms of a CFTR potentiator compound stabilize the active ingredient through specific solvent inclusion.

Novel Salmonella bacteriophage composition targets specific bacterial strains through acid and heat resistant viral infection mechanisms.

Modifying peptide sequences with specific functional groups resolves the contradiction between efficacy and side effects in migraine treatment.

Polyglycerol monolaurin mixtures inhibit C. difficile growth without destroying beneficial flora, overcoming antibiotic non-selectivity and resistance risks.

Nucleic acid amplification assays detect Mycobacterium complex and resistance mutations in rpoB, katG, and inhA regions to resolve diagnosis delays.

SAA-3 protein accelerates mammary gland involution and inhibits bacterial translocation, reducing intra-mammary infections without antibiotics.

LpfA antigen targets Peyer's patches to stimulate mucosal immunity against antibiotic-resistant E. coli infections.

Replacing toxic aldehydes with copper halide salts creates a non-corrosive disinfectant that sustains antimicrobial activity via hydroxyl radical generation.

Exogenous IFIT polypeptides increase cellular concentration to reduce viable mycobacteria, addressing drug-resistant tuberculosis strains.

A choline borate complex increases shrimp survival rates against White Spot Syndrome Virus.

Removing anionic surfactants from oral care formulations boosts quaternary ammonium bioavailability and bactericidal efficacy while reducing tooth staining.

Magnolia extract combined with antioxidants provides synergistic antibacterial activity against Streptococcus mutans while reducing tooth discoloration risks.

Formula I and II structures bind PARP enzymes to treat cancers with impaired DNA repair pathways while minimizing off-target effects.

Multivalent CD20-binding molecules link Shiga toxin effector polypeptides to target cells, resolving the bottleneck of poor antigen internalization.

Multispecific fusion proteins bind V-tip and surface proteins, blocking effector injection into eukaryotic cells.

Selective diazepine sulfonamide agonists modulate the bombesin receptor subtype-3 to address obesity and diabetes while reducing adverse side effects.

Composite branched amino acid probes improve metabolic stability and bioavailability of peptide therapeutics.

Peptide vaccines link viral epitopes to artificial T helper markers, enabling DIVA diagnostics that differentiate infected from vaccinated pigs.

General formula I compounds bind human CGRP receptors to inhibit calcitonin gene-related peptide action.